Insider Selling: BioAge Labs (NASDAQ:BIOA) CEO Sells 233,107 Shares of Stock

BioAge Labs, Inc. (NASDAQ:BIOA) CEO Kristen Fortney sold 233,107 shares of the business’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $18.12, for a total value of $4,223,898.84. Following the transaction, the chief executive officer directly owned 976,949 shares of the company’s stock, valued at $17,702,315.88. This trade represents a 19.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

BioAge Labs Price Performance

NASDAQ:BIOA traded down $1.41 during trading hours on Thursday, hitting $21.51. The company’s stock had a trading volume of 885,351 shares, compared to its average volume of 1,150,796. BioAge Labs, Inc. has a twelve month low of $2.88 and a twelve month high of $24.00. The stock has a fifty day simple moving average of $11.68 and a 200-day simple moving average of $7.43. The company has a market capitalization of $771.13 million, a P/E ratio of -14.15 and a beta of 1.38.

BioAge Labs (NASDAQ:BIOA) last issued its earnings results on Thursday, November 6th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.11. The business had revenue of $2.05 million for the quarter.

Hedge Funds Weigh In On BioAge Labs

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Police & Firemen s Retirement System of New Jersey acquired a new stake in BioAge Labs during the 2nd quarter valued at approximately $27,000. Russell Investments Group Ltd. bought a new stake in shares of BioAge Labs in the 3rd quarter valued at $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of BioAge Labs by 85.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after purchasing an additional 5,976 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of BioAge Labs during the second quarter worth approximately $57,000. Finally, Intech Investment Management LLC bought a new stake in BioAge Labs during the 2nd quarter valued at $60,000.

Wall Street Analyst Weigh In

A number of analysts have weighed in on BIOA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research note on Thursday, October 30th. Citigroup boosted their price objective on BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $15.00.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.